Pfizer Inc. announced on April 21, 2026, that it will present new data from its oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, in Chicago. The data include more than 40 abstracts, with three late-breaking sessions and eight oral presentations, covering established therapies and next-generation candidates. Key highlights include a seven-year update from the Phase 3 CROWN study of LORBRENA in ALK-positive non-small cell lung cancer, and a late-breaking presentation of progression-free survival and overall survival data from Cohort 3 of the BREAKWATER trial evaluating a BRAFTOVI regimen in BRAF V600E-mutant metastatic colorectal cancer.
This announcement comes amid broader EU efforts to strengthen health biotechnology and pharmaceutical innovation. On December 16, 2025, the European Commission proposed the Biotech Act, aiming to simplify regulatory processes and boost EU-based biomanufacturing. Commissioner Olivér Várhelyi, at the Euronews Health Summit on March 17, 2026, emphasized the need to preserve Europe's healthcare model through innovation, while on December 3, 2025, he unveiled a Health Package including a Cardiovascular Plan and the Biotech Act to address aging populations and global competition.
Pfizer's data also highlight potential earlier-line treatments for prostate and breast cancers, including a late-breaking presentation from the Phase 3 TALAPRO-3 study of TALZENNA plus XTANDI in metastatic castration-sensitive prostate cancer, and results from the HER2CLIMB-05 study of TUKYSA as first-line maintenance for HER2-positive metastatic breast cancer. The company will also present updated Phase 2 data for PF-08634404, a bispecific antibody targeting PD-1 and VEGF, and sigvotatug vedotin, an integrin-directed ADC, in non-small cell lung cancer.
The EU's clinical trials ecosystem is under scrutiny. On April 18, 2026, the EMA, European Commission, and Heads of Medicines Agencies pushed a target to raise EU clinical trials by 11.1%, aiming to add 500 multinational trials over five years. A Frontier Economics study estimated this could create 35,000 trial places and €4 billion in economic impact, reversing a decade-long decline. Meanwhile, on April 19, 2026, Belgium's clinical research competitiveness was flagged as strained by slow patient access to new therapies, with industry warnings that regulation and reimbursement must evolve.
"For people living with cancer and their families, every moment matters. We are moving with urgency to drive advances that have the potential to change standards of care." The data reinforce Pfizer's ability to advance breakthroughs that may redefine clinical practice, aligning with EU goals to foster innovation and competitiveness in the pharmaceutical sector.